# A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

> **NCT04740931** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 729 (actual)

## Conditions studied

- Macular Edema
- Central Retinal Vein Occlusion
- Hemiretinal Vein Occlusion

## Interventions

- **DRUG:** Faricimab
- **DRUG:** Aflibercept
- **PROCEDURE:** Sham Procedure

## Key facts

- **NCT ID:** NCT04740931
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-02
- **Primary completion:** 2022-08-09
- **Final completion:** 2023-07-12
- **Target enrollment:** 729 (ACTUAL)
- **Last updated:** 2024-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04740931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04740931, "A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04740931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*